A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCT

Inclusion Criteria: 1. Patients with CAEBV or EBV-HLH who are eligible for allogeneic hematopoietic stem cell transplantation meet one of the following criteria: ①EBV-DNA (PBMC or plasma) was still more than 103 before transplantation；②Positive for Cerebrospinal fluid EBV-DNA； ③Abnormal phenotypic lymphocytes could still be detected in bone marrow immunotyping； ④Measurable EBV-related lesions on imaging； 2. ≤65 years，ECOG :0-2； 3. Cardiac EF≥40%, creatinine clearance ≥50%; aminotransferase（ALT/AST）\<200U/L。； 4. In patients with HLH, HLH efficacy ≥Partial Response after prior treatment is required； 5. Estimated survival time is longer than three months； 6. Agree to sign the Informed Consent Form。 Exclusion Criteria: 1. Patients with evidence of grade II or more serious heart disease according to the New York Heart Association (NYHA) score (including Grade II) ; Clear diagnosis of cirrhosis； 2. Active infections other than EBV that have not yet been controlled； 3. Positive for hepatitis B virus or hepatitis C virus； 4. Active massive hemorrhage of internal organs (including gastrointestinal hemorrhage, alveolar hemorrhage, intracranial hemorrhage, etc.)； 5. Also participation in other interventional clinical studies within 4 weeks